中文
Home
Protocols
Research fields
Biochemistry (1140)
Biophysics (87)
Cancer Biology (362)
Cell Biology (1668)
Developmental Biology (238)
Immunology (504)
Microbiology (986)
Molecular Biology (890)
Neuroscience (529)
Plant Science (905)
Stem Cell (196)
Systems Biology (253)
Bio-protocol journal
Special issues
Lab protocol hub
Request a Protocol
Submit
Submit a protocol
Author guidelines
About
|
A high-quality database for basic life science protocols
Protocols
Research fields
Biochemistry (1140)
Biophysics (87)
Cancer Biology (362)
Cell Biology (1668)
Developmental Biology (238)
Immunology (504)
Microbiology (986)
Molecular Biology (890)
Neuroscience (529)
Plant Science (905)
Stem Cell (196)
Systems Biology (253)
Bio-protocol journal
Special issues
Lab protocol hub
Request a Protocol
Submit
Submit a protocol
Author guidelines
About
This protocol was submitted by the author(s) of the original paper via Bio-protocol's "
Request a Protocol
" feature.
Original Research Paper
Co-delivery of IKBKE siRNA and cabazitaxel by hybrid nanocomplex inhibits invasiveness and growth of triple-negative breast cancer
DOI: 10.1126/sciadv.abb0616
Science Advances , Jul 14, 2020
Related protocols in the same article
+ Show more
Update your protocol
Cellular uptake study
Kun Cheng
Original Research Paper
Co-delivery of IKBKE siRNA and cabazitaxel by hybrid nanocomplex inhibits invasiveness and growth of triple-negative breast cancer
Science Advances
, Jul 14, 2020
DOI:
10.1126/sciadv.abb0616
Last updated date: Sep 22, 2020
View: 249
Download PDF
How to cite
Copy protocol link
Q&A
How to cite:
Readers should cite both the Bio-protocol article and the original research article where this protocol was used:
1. Cheng, K. (2020). Cellular uptake study. Bio-protocol.
bio-protocol.org/prep517
.
2. Zhao, Z., Li, Y., Liu, H., Jain, A., Patel, P. and Cheng, K.(2020). Co-delivery of IKBKE siRNA and cabazitaxel by hybrid nanocomplex inhibits invasiveness and growth of triple-negative breast cancer . Science Advances 6(29). DOI:
10.1126/sciadv.abb0616
Copyright:
Content may be subjected to copyright.
Q&A
Find out more
We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.